Sex Disparities in Asthma Development and Clinical Outcomes: Implications for Treatment Strategies.

A gender-related disparity exists in asthma morbidity and mortality, which shifts at around puberty from a male predominance to a female predominance. This is clinically reflected in the fact that asthma that occurs in childhood (childhood-onset asthma) mainly affects boys, and that asthma that occurs in adulthood (adult-onset asthma) mainly affects women. Adult-onset asthma is often non-atopic, more severe, and associated with a poorer prognosis, thus posing a marked burden to women's health and healthcare system. Many factors have been indicated to explain this gender-related disparity, including sociocultural and environmental factors as well as biological sex differences (genetic, pulmonary and immunological factors). It has long been suggested that sex hormones may be implicated in at least these biological sex differences. Overall, the evidence remains equivocal for the role of most sex hormones in asthma pathogenesis and clinical outcomes. Well-designed randomized clinical trials are required assessing the potential preventive or therapeutic effects of hormonal contraceptives on asthma in women, thereby helping to advance the evidence to inform future practice guidelines. The mechanisms underlying the role of sex hormones in asthma are complex, and our understanding is not yet complete. Additional mechanistic studies elucidating sex hormone signaling pathways and their interactions involved in the pathogenesis and clinical manifestations of asthma will help to identify potential sex hormone-driven asthma endotypes and novel therapeutic targets, providing the basis for a more personalized asthma management strategy.

Age- and Gender-Related Disparities in Asthma

Asthma is a common, heterogenous disease characterized by reversible airway obstruction afflicting around 1–18% of the population in different countries.1 It is estimated that in 2019 asthma affected around 262 million people and caused 461 thousand deaths worldwide,2 constituting a major global health problem. For decades, an age- and gender-related difference in asthma has been reported across different continents. During childhood, asthma is more common and severe in boys than in girls.3–19 Then, a shift takes place around puberty from which time asthma becomes more common and severe in women than in men.3–5,7,9–33

Childhood-Onset and Adult-Onset Asthma

The switch in asthma from a male predominance in childhood to a female predominance from puberty onwards is clinically reflected in the fact that asthma that occurs in childhood (childhood-onset asthma) mainly affects boys, whilst asthma that occurs in adulthood (adult-onset asthma) mainly affects women.9,10,17,18 Although a specific age cut-off for adult-onset asthma has not been determined, the estimated incidence of adult-onset asthma from general population cohort studies has been reported to be on average 5.9 cases per 1000 person-years in women and 4.4 cases per 1000 person-years in men.24 Compared to childhood-onset asthma, adult-onset asthma is often non-atopic, more severe, and associated with persistent airflow limitation, a faster decline in lung function and a poorer prognosis, thereby representing a distinct clinical phenotype of asthma.34–39 The age at onset of asthma is a critical determinant of asthma remission such that asthma remission becomes rarer as the age at onset of asthma increases.10,40 Childhood-onset asthma has a high remission probability reaching up to 60%,10 whereas adult-onset asthma tends to be chronic and has a considerably low remission probability ranging from 3% to 18%.10,40–45 Due to the low remission probability of adult-onset asthma together with the relatively high incidence among women, adult-onset asthma became the dominant phenotype among women with asthma early by age 32–40 years in a US study (adult-onset asthma defined as age at onset of ≥18 years),46 and by age 30–38 years in two Finnish studies (age at onset of ≥15 or 18 years),17,18 while childhood-onset asthma remained the dominant phenotype among men with asthma by age 50–54 years.17,18 These studies indicate that adult-onset asthma poses a marked burden to women’s health, healthcare system and the larger society.

Hypotheses Linking Sex Hormones and Asthma

Several hypotheses have been proposed to explain the age- and gender-related variations in asthma, including sociocultural and environmental factors as well as biological sex differences (genetic, pulmonary and immunological factors).47 Because the switch in asthma incidence and clinical morbidity between males and females coincides with the onset of puberty, which involves different increases in the activities of sex hormones (estrogens, progestogens and androgens), sex hormones have been suggested to play a major role in theses biological sex differences.47,48 In reproductive-age women, the key hormonal transition points including puberty, menstruation and pregnancy which are characterized by increases/fluctuations in the levels of endogenous sex hormones, may increase the risk of developing asthma and worsening of clinical outcomes, whereas suppression of the activities of endogenous sex hormones (eg, through hormonal contraceptives) may decrease the risk. In menopausal women, the onset of menopause and thus a reduction in the activities of endogenous sex hormones may decrease the risk of developing asthma and improve clinical outcomes, whereas use of menopausal hormone therapy (MHT) to enhance the levels of endogenous sex hormones may increase the risk and worsen clinical outcomes. In addition, male sex hormones (androgens) may confer a protective effect on the susceptibility to asthma.49 In all, the ratio of female sex hormones to male sex hormones may play a crucial role in the pathogenesis and clinical manifestations of asthma. Although these hypotheses seem intriguing and promising, from decades of intensive investigations evidence linking sex hormones to asthma remains equivocal.48,50,51 In this review, we summarize the evidence on the potential role of sex hormones in asthma pathogenesis and its clinical manifestations from epidemiological, clinical, and experimental studies, with a particular focus on epidemiological and clinical data in females. We also discuss the potential clinical implications of sex hormones in asthma prevention and management, and provide some perspectives for future research in this area. Table 1 and Table 2 respectively summarize the epidemiological evidence on the role of sex hormones in asthma onset and clinical outcomes.

Table 1

Summary of Epidemiological Evidence on Sex Hormones and Asthma Onset

Exposure	Epidemiological Evidence
Puberty	A systematic review51 including six cohort studies with 18,272 women reported that compared to typical menarche (11–13 years), early menarche (< 11 years) was associated with an increased risk of new-onset asthma after puberty. Two MR studies52,53 found similar results.
Menstruation	A systematic review51 including three cross-sectional studies reported that compared to regular menstruation, irregular menstruation was associated with increased odds of current asthma. However, because of the cross-sectional design, causal inference is impossible.
Pregnancy	Three cross-sectional studies56–58 investigated association between pregnancy history and asthma odds, but reported inconsistent results. Likewise, causal inference is impossible because of the cross-sectional design.
Menopause	Conflicting evidence exists for menopause and asthma: the UK national cohort study62 of 353,173 women and the Nurses’ Health Study59 of 64,237 women reported that postmenopausal women had a decreased risk of new-onset asthma compared to pre- or peri-menopausal women; by contrast, the French E3N cohort study61 of 67,872 women and the Respiratory Health in Northern Europe study60 of 2322 women found that compared to premenopausal women, peri- or post-menopausal women had an increased asthma risk.
Hormonal contraceptives	The evidence on hormonal contraceptives and asthma is mixed: the UK national cohort study64 of 564,896 women and a German community-based cohort study63 of 1191 women reported that use of hormonal contraceptives was associated with a decreased risk of new-onset asthma compared to non-use, and that longer duration of use was associated with a lower asthma risk than shorter duration64; however, the Nurses’ Health Study59 of 36,094 women found that use of hormonal contraceptives was associated with an increased asthma risk.
Menopausal hormone therapy (MHT)	The evidence on MHT and asthma is mixed: an umbrella review65 including five cohort studies with 163,161 women and a Danish register-based nested case-control study66 of 379,649 women reported that use of MHT was associated with an increased risk of new-onset asthma compared to non-use; however, the UK national cohort study62 of 353,173 women found that use of MHT was associated with a decreased asthma risk, and that longer duration of use was associated with a lower asthma risk than shorter duration.
Serum levels of sex hormones	A cross-sectional study67 reported that an elevated serum level of estradiol was associated with decreased odds of current asthma in both women and men. Three cross-sectional studies67–69 found that an elevated serum level of (free) testosterone was associated with decreased odds of asthma in females and/or males. However, causal inference is impossible because of the cross-sectional design.

Abbreviations: MHT, menopausal hormone therapy; MR, Mendelian randomization.

Table 2

Summary of Epidemiological Evidence on Sex Hormones and Asthma Progression and Clinical Outcomes

Exposure	Epidemiological Evidence
Puberty	The Childhood Asthma Management Program study71 prospectively tracked 418 children with asthma through childhood and adolescence, and found that asthma symptoms tended to worsen in girls but improve in boys.
Menstruation	Around 10–40% of women with asthma experience cyclical worsening of asthma symptoms during the perimenstrual period, a phenomenon known as perimenstrual asthma (PMA).72–75 The pathophysiological mechanisms of PMA remain poorly understood.
Pregnancy	During pregnancy, approximately one third of women with asthma experience improvement, one third show worsening of symptoms, and one third remain unchanged.83–86 Asthma tends to return to the pre-pregnancy state after delivery.91–93 Some studies88,90,97,100–106 investigated association between fetal gender and maternal asthma, but reported inconsistent results.
Menopause	To our best knowledge, no studies have investigated asthma progression during menopausal transition among women with asthma. Several longitudinal studies107–110 and a MR study111 looked at the trajectory of lung function during menopausal transition among healthy women, but reported contradictory results.
Hormonal contraceptives	Among asthmatic patients, the UK national cohort study118 of 83,084 women and the Children’s Health Study117 of 192 women found that use of hormonal contraceptives was associated with a decreased risk of severe asthma exacerbations or wheezing symptoms compared to non-use. The therapeutic effects of hormonal contraceptives on PMA were reported in several case reports and series,81,112,113 but not in another case report.114
Menopausal hormone therapy (MHT)	The UK national cohort study124 of 31,656 women with asthma found that use of MHT was associated with an increased risk of severe asthma exacerbations compared to non-use, and that longer duration of use was associated with a higher risk of asthma exacerbations than shorter duration. Several uncontrolled before-and-after studies119–121 investigated the effects of MHT on lung function or asthma medication use in women with asthma, but reported conflicting results.
Serum levels of sex hormones	Among asthmatic patients, a cross-sectional study125 reported that an elevated serum level of estradiol was associated with decreased lung function in girls. Three cross-sectional studies68,69,125 found that an elevated serum level of (free) testosterone or DHEAS was associated with increased lung function and/or deceased odds of asthma symptoms in females and/or males. However, causal inference is impossible because of the cross-sectional design.

Abbreviations: DHEAS, dehydroepiandrosterone sulfate; MHT, menopausal hormone therapy; MR, Mendelian randomization; PMA, perimenstrual asthma.

Epidemiological Evidence on Sex Hormones and Asthma Onset

Puberty

A systematic review including six prospective cohort studies with 18,272 women found that compared to typical menarche (11–13 years), early menarche (<11 years) was associated with increased odds of new-onset asthma after puberty (odds ratio [OR] 1.49, 95% confidence interval [CI] 1.14–1.94).51 The results were further supported by Mendelian randomization (MR) studies,52,53 in which genetic variants known to affect age at puberty were used as proxies (ie, instrumental variables assumed not to be affected by typical confounding factors or reverse causation54) to estimate the causal effect of age at puberty on asthma onset. From the UK Biobank study,52 MR analyses based on 243,316 women aged 40–69 years using 254 genetic variants for age at menarche found that compared with normal menarche (12–14 years), early menarche (<12 years) was associated with an 8% increase (OR 1.08, 95% CI 1.04–1.12) and late menarche (>14 years) with an 8% decrease (OR 0.92, 95% CI 0.89–0.97) in asthma odds, suggesting a continuous protective effect of increasing age at puberty. MR analyses of the data from the Taiwan Children Health Study of 1475 girls aged 11–12 years using six genetic variants for early pubertal maturation reported that early puberty was associated with a tendency towards increased asthma odds (OR 1.11, 95% CI 0.83–1.48).53 Interestingly, a similar pattern between puberty and asthma was also observed in males, with increased odds of asthma for early puberty and decreased odds for late puberty.52,53 Possible explanations may include greater cumulative exposure to female sex hormones due to early puberty in females as well as other biological and psychological factors that accompany early puberty in both males and females.52,55

Menstruation

A systematic review including three cross-sectional studies with 9202 women found that compared to regular menstruation, irregular menstruation was associated with increased odds of current asthma (OR 1.59, 95% CI 1.23–2.05).51 However, due to the cross-sectional design, we cannot assume any causal relationship in these results.

Pregnancy

Evidence on pregnancy and asthma onset is sparse. Cross-sectional analysis of the data from the Tasmanian Longitudinal Health Study (TAHS) of 388 women aged 29–32 years suggested that odds of current asthma increased with number of live births in parous women (OR 1.50 per birth, 95% CI 1.01–2.23).56 However, further cross-sectional analysis of the TAHS data of 2764 women aged 44 years found no evidence of association between pregnancy history (number of live births and age at first pregnancy) and current asthma.57 Similarly, in another cross-sectional study of 1755 non-smoking women aged 35–74 years,58 no evidence of association was found between asthma and number of pregnancies or number of live births. Likewise, causal inference is impossible because of the cross-sectional design in these studies.

Menopause

Conflicting evidence exists for the impact of menopause on asthma onset. The Nurses’ Health Study of 64,237 women aged 34–68 years with 425,787 person-years of follow-up reported that compared with premenopausal women, naturally postmenopausal women who were never users of MHT had a decreased risk of developing asthma (hazard ratio [HR] 0.65, 95% CI 0.46–0.92).59 This result was subsequently contradicted by two other prospective cohort studies.60,61 The Respiratory Health in Northern Europe study of 2322 women aged 45–65 years reported that peri- or post-menopausal women experienced increased odds of asthma compared to premenopausal women, with ORs ranging from 2.11 to 3.44.60 The French E3N cohort study of 67,872 women aged 41–68 years found that naturally peri- or post-menopausal women who were overweight or obese as well as surgically postmenopausal women had an increased risk of asthma compared to premenopausal women, with HRs ranging from 1.33 to 2.08.61 However, in a recent UK national retrospective cohort study of 353,173 women aged 46–70 years with 1,340,423 person-years of follow-up,62 postmenopausal women were found to have a decreased risk of developing asthma compared to perimenopausal women (HR 0.88, 95% CI 0.83–0.92).

Hormonal Contraceptives

Current evidence on hormonal contraceptives and asthma is mixed. The Nurses’ Health Study of 36,094 postmenopausal women with 295,694 person-years of follow-up reported that past use of hormonal contraceptives was associated with an increased risk of developing asthma compared to non-use (HR 1.57, 95% CI 1.16–2.12).59 However, this result was contradicted by two subsequent studies. In a German prospective community-based cohort study of 1191 girls aged 9–11 years followed into early adulthood (19–24 years old),63 use of hormonal contraceptives was found to be associated with decreased odds of developing asthma (OR 0.27, 95% CI 0.12–0.58). In a recent national, longitudinal UK cohort study of 564,896 women aged 16–45 years with 3,597,146 person-years of follow-up,64 use of hormonal contraceptives and its subtypes (estrogen plus progestin therapy and progestin-only therapy) was associated with a decreased risk of developing asthma, with HRs ranging from 0.59 to 0.70. Furthermore, longer duration of use was associated with a lower risk of asthma than shorter duration.64

Menopausal Hormone Therapy

The evidence on MHT and new-onset asthma in menopausal women remains mixed. An umbrella review including five prospective cohort studies with 163,161 women reported that MHT use was associated on average with a 1.41-fold (95% CI 1.09–1.81) increased risk of new-onset asthma compared to non-use.65 Similarly, in a recent nested case-control study based on the Danish registers,66 which included 34,533 women with asthma and 345,116 without asthma aged 40–65 years, use of MHT and its subtypes (estrogen-alone therapy and estrogen plus progestin therapy) was associated with an increased risk of developing asthma, with HRs ranging from 1.18 to 1.63. However, these results were contrasted by a UK national retrospective cohort study,62 the largest longitudinal study on the topic to date, which included 353,173 women aged 46–70 years with 1,340,423 person-years of follow-up, and found that use of MHT and its subtypes was associated with a decreased risk of asthma, with HRs ranging from 0.78 to 0.89, and that longer duration of use was associated with a decreased asthma risk in a dose-response manner.

Serum Levels of Sex Hormones

In a US nationwide cross-sectional study of 7615 adults (3662 women and 3953 men) aged 18–79 years,67 elevated serum levels of both free testosterone (the highest quartile [Q4] versus the lowest [Q1]: OR 0.59, 95% CI 0.37–0.91) and estradiol (Q4 versus Q1: OR 0.43, 95% CI 0.23–0.78) were associated with reduced odds of current asthma in obese women, and an elevated serum estradiol level was associated with reduced odds of current asthma in non-obese men (Q4 versus Q1: OR 0.44, 95% CI 0.21–0.90). Similarly, in a UK cross-sectional study of 256,419 adults (123,921 women and 132,498 men) aged 40–69 years,68 an elevated serum level of free testosterone was associated with reduced odds of physician-diagnosed asthma in both women (Q4 versus Q1: OR 0.67, 95% CI 0.64–0.71) and men (Q4 versus Q1: OR 0.87, 95% CI 0.82–0.91). Further, in another US cross-sectional study of 7584 participants (3808 females and 3776 males) with a broader age range (6–80 years),69 an elevated serum testosterone level was associated with lower odds of current asthma in both females (for each 25-unit change in serum testosterone: OR 0.70, 95% CI 0.60–0.91) and males (for each 25-unit change in serum testosterone: OR 0.97, 95% CI 0.94–0.99). Of note, because of the cross-sectional design, causal inference is impossible. Interestingly, a recent two-sample MR study across two large datasets from the Trans-National Asthma Genetics Consortium genome-wide association study of asthma and UK Biobank with over 460,000 individuals,70 indicated a protective effect of genetically elevated sex hormone-binding globulin (SHBG) on asthma, with ORs ranging from 0.83 to 0.86, per unit increase in natural log SHBG, and that the effect was more pronounced among females than males. However, due to the complex genetic correlation between SHBG and testosterone as well as other hormones (eg, estrogens), further studies are needed to disentangle the downstream effects of SHBG on asthma and the mechanistic pathways involved.70

Epidemiological Evidence on Sex Hormones and Asthma Progression and Clinical Outcomes

Studies on natural progression of asthma through puberty are scant. The Childhood Asthma Management Program study prospectively tracked 418 children (184 girls and 234 boys) aged 5–12 years with mild-to-moderate asthma through childhood and adolescence, with daily records of asthma symptoms for five years.71 It found that at approximately nine years of age when the Tanner stages (a grading system used for pubertal staging) began to increase, asthma symptoms started to worsen in girls, but not in boys. At late puberty, asthma symptoms continued to worsen in girls, while asthma symptoms started to improve in boys.71

Around 10–40% of women with asthma experience cyclical worsening of asthma symptoms during the perimenstrual period, a phenomenon known as perimenstrual asthma (PMA).72–75 PMA is operationally defined as an aggravation of asthma symptoms or a decrease in lung function immediately preceding or during the menstrual phase of the female cycle.72 Women with PMA tend to have increased asthma rescue medication use and more emergency room visits and hospitalizations for asthma, compared to women without PMA.73,76–79 Some studies have linked PMA with severe, difficult-to-control asthma or near-fatal and fatal events.74,75,79–82 However, the pathophysiological mechanisms of PMA remain poorly understood. In light of the well-known hormonal fluctuations throughout the menstrual cycle and the cyclical nature of PMA, it has been hypothesized that female sex hormones may likely play a pivotal role in PMA, although the potential mechanisms through which sex hormones may influence the course of asthma remain unclear.72 If fluctuations in the levels of female sex hormones during the menstrual cycle cause cyclical changes in the severity of asthma, it seems plausible that suppressing the fluctuations through appropriate hormonal contraceptives could reduce the perimenstrual worsening of asthma and improve asthma control in PMA patients. However, there is a paucity of rigorous evidence in this regard; several case reports and series investigated the potential therapeutic effects of hormonal contraceptives on PMA, but yielded discordant results.72 A more detailed discussion of the studies is given in a later section on hormonal contraceptives.

A number of studies have shown that the course of asthma may change during pregnancy. The commonly quoted generalization is that during pregnancy, approximately one-third of women with asthma experience improvement, one-third show worsening of symptoms, and one-third remain unchanged.83–86 Women with severe asthma are more likely to experience exacerbations during pregnancy than those with mild disease.86–90 After delivery, asthma tends to return to the pre-pregnancy state.91 Cases of severe life-threatening asthma improving markedly within 24 hours of termination of pregnancy have also been noted.92,93 The mechanisms contributing to the changes in asthma during or after pregnancy are not well understood. In view of the significant changes in sex hormones during pregnancy, sex hormones have been hypothesized to be at least partly responsible for the effects of pregnancy on maternal asthma.94 On the other hand, fetal gender has been suggested to alter maternal inflammatory processes associated with asthma, possibly through the differences in maternal levels of sex hormones by fetal gender, such that maternal inflammation is upregulated in the presence of a female fetus.95–99 However, studies looking at the effect of fetal gender on the course of asthma during pregnancy reported inconsistent results. Several studies found that during pregnancy women with asthma carrying a female fetus were more likely than those carrying a male fetus to have greater airway lability,100 increased steroid use,97,101 or asthma exacerbations,102,103 but these findings were not replicated in other studies.88,90,104–106

To our best knowledge, no studies have looked at the progression of asthma during menopausal transition among women with asthma. Some studies investigated the trajectory of lung function during menopausal transition among healthy women, but reported contradictory results. Several longitudinal studies showed that menopause was associated with reduced lung function parameters (eg, forced vital capacity [FVC], forced expiratory volume in one second [FEV1]).107–110 However, MR analyses of 94,742 naturally postmenopausal women from the UK Biobank found that early menopause (< 45 years) was associated with higher FEV1/FVC and a lower risk of airflow obstruction (OR 0.85, 95% CI 0.82–0.89), compared to normal menopause (45–55 years).111 Given that MR study is generally thought to be free from classical confounding, future longitudinal studies which account for more potential confounders as well as replication of the MR study across different populations may help to understand the inconsistency between the observational and MR findings.

Given that hormonal fluctuations during the menstrual cycle might be responsible for cyclical worsening of asthma symptoms among some women with asthma,72 several case reports and series explored the potential therapeutic effects of hormonal contraceptives on PMA, but reported inconsistent results. Four patients with severe premenstrual exacerbations of asthma resistant to conventional therapy, including high-dose corticosteroids, responded very well to intramuscular progesterone injections.81,112 One case report found that premenstrual exacerbations of asthma improved dramatically following administration of an oral contraceptive consisting of norgestrel and ethinylestradiol.113 By contrast, another case report suggested that an oral contraceptive comprising norgestimate and ethinylestradiol may cause deterioration of PMA.114 Further, some studies investigated the effects of hormonal contraceptives on lung function or asthma exacerbations among an unselected population of reproductive-age women with asthma. In two small prospective studies of 17–18 women with asthma,115,116 women receiving oral combined contraceptive pill compared with those not receiving contraceptive pill had attenuated cyclical change in airway responsiveness to adenosine monophosphate and exhaled nitric oxide levels as well as reduced variations in diurnal peak expiratory flow (PEF), in association with suppression of the normal luteal phase rise in sex hormones. Prospective data from the Children’s Health Study of 192 women with a history of asthma aged 13–28 years reported that use of hormonal contraceptives was associated with reduced occurrence of wheezing symptoms (OR 0.18, 95% CI 0.06–0.56), compared to non-use.117 More recently, in a large longitudinal UK cohort study of 83,084 reproductive-age women with asthma aged 16–45 years with 456,803 person-years of follow-up,118 use of hormonal contraceptives was associated with a small protective effect on severe asthma exacerbations, with incidence rate ratios (IRRs) ranging from 0.92 to 0.96. Taken together, from the available literature, hormonal contraceptives may be effective in controlling asthma symptoms in some PMA patients and reducing the risk of asthma exacerbations in reproductive-age women with asthma.

Several uncontrolled before-and-after studies evaluated the effects of MHT on clinical outcomes of asthma in menopausal women, but reported conflicting results. In 32 postmenopausal women with asthma using glucocorticoids, use of cyclical transdermal 17β-estradiol and medroxyprogesterone acetate improved lung function and reduced use of glucocorticoids and frequency of asthma exacerbations.119 By contrast, use of transdermal estradiol decreased PEF values and increased use of bronchodilators in 15 postmenopausal women with asthma.120 However, in another study of 20 postmenopausal women with asthma,121 no evidence was found that oral estrogen could affect FEV1, PEF or use of bronchodilators. Of note, due to potential limitations in uncontrolled before-and-after studies,122,123 these findings should be viewed with caution. To our best knowledge, there is only one longitudinal cohort study investigating the effects of MHT on clinical outcomes of asthma. In a national UK cohort study of 31,656 peri- and post-menopausal women with asthma aged 46–70 years with 366,678 person-years of follow-up,124 use of MHT and its subtypes (estrogen-alone therapy and estrogen plus progestin therapy) was associated with an increased risk of severe asthma exacerbations compared with non-use, with IRRs ranging from 1.07 to 1.28. Further, longer duration of use was associated with a higher risk of asthma exacerbations than shorter duration.124 Taken together, evidence on the impact of MHT use on clinical outcomes of asthma in menopausal women with asthma is still limited.

In a small US cross-sectional study of 68 children with asthma aged 6–18 years,125 an elevated serum level of estradiol was associated with decreased FEV1 and FVC in girls, whereas an elevated serum level of dehydroepiandrosterone sulfate (DHEAS) was associated with increased FEV1 and FVC and deceased asthma symptoms in boys. Similarly, in another US cross-sectional study of 312 asthma patients aged 6–80 years,69 an elevated serum testosterone level was associated with increased FEV1 in both sexes. Further, in a UK cross-sectional study of 28,303 adults with asthma (14,056 women and 14,247 men) aged 40–69 years,68 an elevated serum level of free testosterone was associated with lower odds of wheezing symptoms (Q4 versus Q1: OR 0.78, 95% CI 0.71–0.87) and asthma hospitalization (Q4 versus Q1: OR 0.73, 95% CI 0.56–0.95) in women, and with lower odds of wheezing symptoms (Q4 versus Q1: OR 0.86, 95% CI 0.77–0.95) in men. Taken together, current evidence linking circulating sex hormones and clinical outcomes of asthma suggests that estradiol is associated with impaired lung function, while androgens including testosterone and DHEAS are associated with an improvement in lung function and asthma symptoms. However, the evidence is hampered by inherent limitations in the cross-sectional design.

Mechanistic Evidence on Sex Hormones and Asthma Pathogenesis

Asthma is a heterogenous disease characterized by airway inflammation, airway hyperresponsiveness (AHR), and airway remodeling.126 Multiple inflammatory pathways can mediate airway inflammation in asthma, mainly including eosinophilic type 2 high inflammation (allergic or non-allergic) and non-eosinophilic type 2 low inflammation (neutrophilic or pauci-granulocytic).126 Eosinophilic airway inflammation is mainly induced by increased production of type 2 cytokines (eg, interleukin [IL]-4, IL-5, IL-13) from T helper 2 (TH2) cells or group 2 innate lymphoid cells (ILC2s), which drive infiltration of eosinophils into the lung with or without increased immunoglobulin E (IgE) (Figure 1).127 Neutrophilic airway inflammation is primarily mediated by increased secretion of cytokines (eg, IL-17, IL-22, interferon-γ [IFN-γ]) from TH1 cells, TH17 cells or ILC3s, which activate macrophages and promote release of neutrophilic chemokines (Figure 1).126,128 While eosinophilic airway inflammation is considered to be the most common among asthma patients, neutrophilic airway inflammation is present in many patients and associated with late-onset and more severe forms of asthma.127,129 Mounting mechanistic evidence suggests that sex hormones can act directly on airway and immune cells via different inflammatory pathways and play an important role in the pathogenesis of asthma, which has been reviewed extensively elsewhere.49,130–132 Here, we provide a brief discussion and a brief schematic (Figure 1) of some of the experimental evidence from human cells and animal studies.

Figure 1

Schematic of eosinophilic and neutrophilic airway inflammation in asthma. Summary of sex differences and the role of sex hormone signaling in airway inflammation based on experimental evidence from human cells and animal studies are shown in the box below the schematic.

Gender-Related Differences

In patients with moderate-to-severe asthma, women had a higher number of circulating ILC2s than men.133 In another study, women had a higher number of circulating microRNA (miR)-155-expressing ILC2s than men had, regardless of asthma diagnosis.134 Interestingly, ILCs and TH cells from women responded to various stimuli with higher miR-155 expression levels than male-derived cells, and miR-155+ILC2s from women correlated with IL-5 levels in serum whereas male-derived cells did not.134 TH17 cells from women with severe asthma had increased IL-17A production compared to that from men with severe asthma.135 In mouse models of airway inflammation, ILC2s isolated from female mice had higher expression of IL-5 and IL-13 than that from male mice,136 and female mice had increased type 2 cytokines, IL-17A protein expression, TH2 cells, eosinophils, neutrophils and macrophages in the lung, and serum total and antigen-specific IgE compared to male mice.133,137–144 These data suggest that there is a gender-related difference in airway inflammation, and sex hormones may play an important role in the pathogenesis of asthma.

Estrogens and Progestogens

In mouse models of allergic airway inflammation, ovariectomized female mice had decreased levels of eosinophils and type 2 cytokines in the lung and reduced AHR to methacholine, compared to sham-operated female mice.145,146 Estradiol treatment in ovariectomized mice partially restored AHR and levels of eosinophils and IL-5.145,147 However, it was also reported that ovariectomized mice had increased AHR compared to sham-operated mice, which was reversed after estradiol administration.148,149 Several studies used estrogen receptor (ER-α and ER-β) knockout mice to investigate the role of ERs in modulating airway inflammation, AHR or airway remodeling. ER-α knockout mice had lower levels of IL-5, IL-13 and eosinophils in the lung, and reduced IL-33 release, AHR and remodeling, compared to wild-type mice,150,151 though in another study ER-α knockout mice had increased AHR.152 ER-β knockout mice had increased AHR and remodeling compared to wild-type mice,150 and administration of an ER-β agonist reduced AHR and remodeling.153 It seems that ER-α and ER-β play an opposite role in the pathogenesis of allergic asthma. In addition, progesterone treatment increased levels of IL-4, IL-5 and eosinophils in the lung, serum levels of total IgE and AHR.154,155 On the other hand, TH17 cells from ovariectomized mice administered estradiol plus progesterone had increased IL-17A production and IL-23 receptor expression compared to that from those administered vehicle.135 Further, TH17 cells from ER-α deficient but not ER-β deficient female mice had decreased proliferation, IL-17A production and IL-23 receptor expression, compared to that from wild-type female mice.156 Mucus production is a significant clinical problem in patients with severe phenotypes of asthma. In human airway epithelial cells, administration of estradiol increased mucin protein production including MUC5AC and MUC5B.157,158 Interestingly, in human non-asthmatic and asthmatic airway smooth muscle cells, prolonged exposure to an ER-α agonist led to increased levels of intracellular calcium, whereas ER-β activation led to decreased levels, suggesting divergent regulation of airway contractility by ER-α versus ER-β.159 Taken together, these data suggest that estrogen signaling possibly through ER-α as well as progestogen signaling may enhance eosinophilic and neutrophilic airway inflammation, mucus production, AHR or airway remodeling.

Androgens

Sham-operated male mice and gonadectomized male mice administered 5α-dihydrotestosterone (5α-DHT, a hormone downstream of testosterone) had decreased lung ILC2s numbers compared to gonadectomized male mice.133 In in vitro studies, IL-5 and IL-13 protein expression was decreased in ILC2s from sham-operated male mice and gonadectomized male mice administered 5α-DHT compared to ILC2s from gonadectomized male mice.133 In mouse models of airway inflammation, sham-operated male mice had decreased TH2 cells, TH17 cells, eosinophils and neutrophils in the lung, AHR and total serum IgE compared to gonadectomized male mice.133,142 Further, dehydroepiandrosterone (DHEA)-treated mice had reduced AHR, and lower levels of eosinophils, IL-4, IL-5 and IFN-γ in the lung and serum total and antigen-specific IgE, compared to non-DHEA treated mice.160,161 In addition, mouse models using a mutated androgen receptor showed that androgen receptor signaling downregulated TH2 cells-mediated, ILC2s-mediated and IL-17A-mediated airway inflammation.133,142 Taken together, these data suggest that androgens may reduce eosinophilic and neutrophilic airway inflammation and AHR.

Clinical Implications

According to the sex hormone hypotheses,48 in reproductive-age women suppression of ovarian secretion of estrogens and progestogens (eg, use of hormonal contraceptives) during the menstrual cycle may decrease the risk of developing asthma and improve clinical outcomes, whereas in menopausal women supplementation of estrogens and progestogens (eg, use of MHT) may increase the risk and worsen clinical outcomes. Although mixed epidemiological evidence existed for the effects of hormonal contraceptives and MHT on asthma risk in women, most studies showed that use of hormonal contraceptives was associated with a decreased risk of developing asthma, while use of MHT was associated with an increased risk. Among reproductive-age women with asthma, most case reports suggested beneficial effects of hormonal contraceptives in alleviating PMA, and several longitudinal cohort studies consistently reported that use of hormonal contraceptives was associated with a decreased risk of having asthma symptoms or exacerbations. Evidence on MHT in menopausal women with asthma is limited and mainly comes from the large national UK cohort study,124 which showed that use of MHT was associated with an increased risk of asthma exacerbations. Currently, there are no special guidelines on the prescription of hormonal contraceptives or MHT to women at risk of developing asthma or with asthma. Whist further studies are being needed to strengthen the evidence, the possible asthma-related benefits and risks of hormonal contraceptives and MHT should be taken into account in the context of their widely accepted benefits and harms.

In addition, the sex hormone hypotheses suggest that androgens may decrease the risk of developing asthma and improve clinical outcomes.48,49 However, evidence in this regard primarily comes from cross-sectional analyses of serum testosterone levels in women or men with or without asthma. In a multi-center, randomized, double-blind, placebo-controlled trial of 281 moderate-to-severe asthma patients aged 18–70 years,162 administration of nebulized DHEAS (70 mg once daily) for six weeks improved asthma control scores compared to placebo, in addition to low-dose inhaled corticosteroid (fluticasone) and long-acting β2-agonist (salmeterol). More evidence on androgens and asthma is needed to inform practice.

Future Perspectives

From the available observational studies on sex hormones and asthma onset in women, robust consistent evidence exists only for the role of puberty. Evidence on menstruation and pregnancy is quite limited and comes only from cross-sectional studies. Further studies with a longitudinal design are required to allow temporality to be assessed. Studies on menopause have reported contradictory results. MR studies using genetic variants for menopause will hopefully provide more insights into this controversy. There is mixed epidemiological evidence for the effects of hormonal contraceptives and MHT on asthma risk. So far, no randomized clinical trial exists on the topic. More robustly designed longitudinal cohort studies taking into account their subtypes, dosages, routes of administration and durations of use across different populations are warranted to provide more clarity. Accounting for these details will not only help to resolve the inconsistencies in observational studies but also provide the basis for potential future clinical trials assessing the efficacy of hormonal contraceptives in primary prevention of asthma in women.

Further longitudinal studies that track women with asthma in a life-course perspective that includes key hormonal transition points, such as puberty, menstruation, pregnancy and menopause, are warranted. Identifying the specific role of each of these hormonal events as well as other associated risk factors will help to predict the course of asthma and optimize care for women with asthma during the various reproductive phases of life. There is increasing epidemiological evidence that use of hormonal contraceptives is associated with a decreased risk of experiencing asthma symptoms or exacerbations among reproductive-age women with asthma. Therapeutic effects of hormonal contraceptives in PMA have also been noted in several case reports. So far, however, there have been no clinical trials investigating the efficacy of hormonal contraceptives in asthma control. In light of the potential beneficial role of hormonal contraceptives as well as the high prevalence of PMA, well-designed randomized clinical trials of use of hormonal contraceptives in women with asthma, especially in those with PMA, should now be performed to assess whether hormonal contraceptives have any therapeutic implications for asthma. This will need to take into account the potential varying effects of hormonal contraceptives by subtype, dosage, route of administration and duration of use on various phenotypes of asthma, thus generating evidence for more individualized asthma management. In addition, DHEAS intake has been suggested to improve short-term asthma symptoms in a randomized clinical trial.162 Further trials of DHEAS with a longer follow-up period across different asthma phenotypes are required to replicate the findings. Lastly, additional longitudinal cohort studies of MHT use in menopausal women with asthma are also warranted.

There are an increasing number of studies that directly measure the circulating levels of sex hormones in relation to asthma. Unfortunately, their ability to infer causality is largely hampered by the inherent limitations in their cross-sectional design. Whenever possible, future studies of serum levels of sex hormones with a longitudinal design should be encouraged, and specific asthma-related outcome measures, such as incidence, remission, exacerbation and mortality, should be used to disentangle the potential complex role of sex hormones during different phases of asthma. There is also a need to understand the role of sex hormones in the underlying immunopathology and the endotypes of different asthma phenotypes, an aspect largely neglected in previous studies.

In patients with moderate or severe asthma, add-on treatment with biologic agents may be considered.1 Currently available biologics are mostly targeted towards type 2 high inflammation, such as omalizumab (anti-IgE), dupilumab (anti-IL-4 receptor α), mepolizumab (anti-IL-5) and benralizumab (anti-IL-5 receptor α), which is generally less common in women than in men.1,127,163 However, gender differences in the efficacy of the biologics in severe asthma have not been extensively investigated.163,164 Some randomized trials explored gender differences in responsiveness to these biologics and did not find differential responses between women and men.165–171 To our knowledge, no human studies have looked at the effects of these biologics on hormonal activity. Future studies are needed to investigate how the biologics could affect hormonal activity as well as whether clinically important differences by gender exist in the efficacy of the biologics in asthma treatment.

Conclusions

The phenomenon that a gender-related switch in asthma development and clinical morbidity coincides with changes in sex hormones has led to the hypothesis that sex hormones may play an important role in asthma pathogenesis and clinical outcomes. Indeed, some women experience changes in asthma symptoms during various reproductive phases of life such as puberty, menstruation and pregnancy. There is increasing epidemiological or clinical evidence showing that suppression of ovarian secretion of female sex hormones (eg, use of hormonal contraceptives) may decrease asthma risk and improve clinical outcomes of asthma, whereas supplementation of female sex hormones (eg, use of MHT) may increase the risk and worsen asthma outcomes.

Epidemiological evidence regarding androgens is limited and mainly comes from cross-sectional studies of serum testosterone levels. Furthermore, mechanistic studies have revealed that estrogen signaling (possibly through ER-α) as well as progestogen signaling promotes and androgen signaling attenuates eosinophilic and neutrophilic airway inflammation. Collectively, evidence is accumulating that sex hormones may modulate the pathogenesis and clinical manifestations of asthma. Further well-designed randomized trials assessing the potential preventive or therapeutic effects of hormonal contraceptives on asthma in women will help to advance the evidence to inform future practice guidelines. The mechanisms underlying the role of sex hormones in asthma are complex, and our understanding is not yet complete. Additional mechanistic studies elucidating sex hormone signaling pathways and their interactions involved in the pathogenesis and clinical manifestations of asthma will help to identify potential sex hormone-driven asthma endotypes and novel therapeutic targets, providing the basis for a more personalized asthma management strategy.